MAM. V. Ananyan

M. V. Ananyan

*This is an algorithmically generated author record based on publicly available information.

M. V. Ananyan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Elena Georgievna Starostina

    M.F. Vladimirsky Moscow Regional Research Clinical Institute

    3 shared publications
  • Е. Г. Старостина

    ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского

    1 shared publication
  • М. В. Ананян

    ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»; ГБУ «Поликлиника №71» Департамента здравоохранения

    1 shared publication

Latest Publications

  • Open Access

    Nutrition specifics in type 2 diabetic patients with binge eating disorder and the effects of glucagonlike peptide I receptor agonists

    by E. G. Starostina, M. V. Ananyan, Е. Г. Старостина, М. В. Ананян

    BACKGROUND: Binge eating disorder (BED) is the most prevalent eating disorder manifesting as episodes with higher than usual food intake uncontrolled by patients. Nutritional specifics, their associations with biological and psychological parameters in Type 2 diabetes mellitus (T2DM) with BED have not been studied. AIM: To identify specific characteristics of nutrition (food choices, food planning, diet barriers [DB]) in T2DM patients with and without BED, their associations with clinical, laboratory, and psychological parameters and their changes over time under treatment of BED. MATERIAL AND METHODS: T2DM patients with and without BED participated in this cross-sectional study. In those with and without BED, we compared the characteristics of nutritional style, clinical, laboratory and psychological parameters (depression, anxiety/anxiousness, some personality characteristics, including alexithymia, and diabetes-dependent quality of life (Qol). In subsequent prospective open-label interventional part of the study, we evaluated changes of the nutrition characteristics in T2DM patients with BED under treatment with glucagon-like peptide I receptor agonists (GLP1-RA) versus no BED treatment. The univariate analysis was performed at α=0,05, logistic regression at α=0,10. RESULTS: The study recruited 273 T2DM patients (176 with and 97 without BED). The BED patients ate less frequently than those without: minimal number of daily food intakes 2,6±1,1 and 2,9±0,8, respectively (р=0,010), food intake skipped 1,5±1,8 and 0,8±1,5 weekly (р=0,001). Compared to no-BED patients, those with BED consumed more sweets (р=0,003), “hidden” fats (eggs, р=0,015; nuts, р=0,027), and alcoholic drinks (р=0,004). In the BED group, there were 23 associations between various foods and clinical and laboratory parameters (9 of them indicated favorable and 14 unfavorable food effects). In the non-BED group, 6 associations were found, all them indicating favorable food effects. In both groups, the most significant DB was “difficult to withdraw sweets”. The BED-specific weighted DB were: “difficult to stick to a diet in unexpected situations”, “when I eat more than allowed, I feel bad”, “sometimes I am not allowed to eat being hungry”, and “I would like to eat foods that I should not eat”. Only in the BED group, there were weak but significant correlations between DB numbers/patient and metabolic parameters: НbA1c (r=0,210, р CONCLUSION: Specific characteristics of nutrition in T2DM patients with BED (less regular food intake, higher intake of unhealthy products and higher numbers of DB, compared to those in T2DM without BED) may negatively affect clinical, laboratory and psychological parameters. Three factors related to nutrition style are associated with increased BED risk and three, with lower risk. The results necessitate a personalized dietary approach to T2DM patients with BED, which requires its timely diagnosis made in primary and secondary care. GLP1-RAs exert no clinically valuable effects on the studied nutrition characteristics in BED patients with T2DM.

  • Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of binge eating disorder in Type 2 diabetic patients: a pilot study in real world clinical practice

    by E. G. Starostina, M. V. Ananyan

    BACKGROUND : Binge eating disorder (BED) is the most prevalent eating disorder in the population, poorly studied in patients with Type 2 diabetes mellitus (T2DM). There are no generally accepted guidelines on pharmacological treatment of BED and no studies with more than 3-month duration. Glucagon-like peptide 1 receptor agonists (GLP1RA) could be a promising class of agents for the treatment of BED in T2DM patients due to their effects on central mechanisms of appetite and satiety regulation. AIM : To assess efficacy and safety of GLP1 RA for treatment of BED in patients with T2D. METHODS : Sixty six outpatients with T2DM and BED participated in this pilot open-label prospective comparative study of 6 mo’ duration followed by a 6 mo follow-up after GLP1RA withdrawal. All 66 continued their previous anti-hyperglycemic agents, 33 patients (50%) were prescribed a GLPRA (dulaglutide, or semaglutide, or lixisenatide combined with glargin). ­Thirty three patients were in the control group without GLPRA. In addition to standard clinical and laboratory examinations, all patients completed tests/questionnaires for assessment of their quality of life, depression, stait/trait anxiety, alexithymia and other personality characteristics, and physical complaints. Changes in BED severity and all other parameters were assessed at 3 and 6 months, and BED severity only was assessed at 6 months after the end of GLP1RA. RESULTS : After 6 months of GLP1RA therapy, 63,6% of the patients were in complete remission of BED (рCONCLUSION : GLP1 receptor agonists are effective, safe and well tolerated in the treatment of BED in Type 2 diabetes patients. They facilitate the achievement of the main goal of BED treatment (complete or partial remission of BED) in 100% of the cases with marked improvements in metabolic and a range of psychological parameters.


  • Open Access

    Binge eating disorder: epidemiological, clinical, pathophysiological, and treatment aspects

    by E. G. Starostina, M. V. Ananyan

    Binge eating disorder (BED) is the most prevalent type of eating disorders encountered in endocrinological practice, with 5 to 66% of obesity patients seeking for losing weight, 10 to 25% of patients with Type 2 diabetes mellitus, and above 70% of Type 2 patients with morbid obesity having BED. BED can seriously challenge the treatment for Type 2 diabetes and obesity, but remains underdiagnosed and undertreated in most cases. The review discussed diagnostic criteria of BED and their evolution during the last three decades, as well as neurochemical, genetic, and psychological components of its pathophysiology and potential role of BED as a new risk factor for Type 2 diabetes. We have also analyzed medical treatments available for an endocrinologist, including potential use of agonists of glucagone-like peptide 1 receptors.